Marshall Edwards Inc.

Press Releases

2003-December-18	Marshall Edwards, Inc. Announces Pricing of Initial Public Offering of 2,080,000 of Common Stock Units at $7.50 Per Unit (in PDF)
2003-September-26	Marshall Edwards, Inc., Announces Intent to List Company on Nasdaq SmallCap and Initial Public Offering of Two Million Common Stock Units (in PDF)
2003-August-5	Marshall Edwards Inc. Appoints New Director (in PDF)
2003-June-18	IDN Approval from the FDA Achieved for Phenoxodiol Oral Form - Phase II Study for Reproductive Cancers Schedules at Yale (in PDF)
2003-June-3	Yale Researchers Discover That Phenoxodiol Combined with Small Doses of Chemotherapy Reduces Ovarian Cancer Tumour Mass by 75 Percent (in PDF)
2003-May-1	Oncogene Publishes Phenoxodiol Data (in PDF)
2003-April-8	Skin Cancer Phase II Trial Approved for Oral Phenoxodiol at Royal North Shore Hospital (in PDF)
2003-April-1	Yale Researchers Report Phenoxodiol Kills Ovarian Cancer Cells (in PDF)
2003-March-3	Marshall Edwards Inc. Phase II Anti-Cancer Program, on Schedule (in PDF)
2004	2004 Press Releases
2002	2002 Press Releases